VSL#3®补充剂可改善长新冠疲劳：DELong#3随机安慰剂对照试验结果
{"_":"VSL#3 supplementation improves fatigue in long COVID: results from the DELong#3 randomized placebo-controlled trial.","sup":["®"]}
摘要(中文译文)
长新冠（Long COVID）常以持续性疲劳和生活质量受损为特征。越来越多的证据表明，肠道菌群失调和免疫调节异常可能促进症状的持续存在。我们评估了益生菌制剂VSL#3®在长新冠患者中的效果。在这项随机、双盲、安慰剂对照试验（ClinicalTrials.gov注册号：NCT05874089）中，具有临床相关疲劳的长新冠患者接受VSL#3®或安慰剂治疗4周。主要终点为采用Chalder疲劳量表（CFS）评估的疲劳改善情况。次要分析和探索性分析包括患者报告结局、肠道菌群谱分析、免疫表型分析、细胞因子分析以及靶向代谢组学。共48例患者完成研究（安慰剂组n=25；VSL#3®组n=23）。与安慰剂相比，补充VSL#3®显著改善疲劳，CFS评分降幅更大（24.24% vs. 6.06%；p=0.037），应答者比例更高（68% vs. 35.7%；p=0.019）。临床获益在停止治疗后持续存在，并伴有部分生活质量及胃肠道症状领域的改善。补充VSL#3®与健康相关细菌类群的选择性富集相关，包括、 、 和 ，同时伴随炎症及免疫相关通路的调节。探索性多组学分析发现，微生物群来源代谢物、免疫标志物与临床结局之间存在协同关联。补充VSL#3®改善了长新冠患者的疲劳及部分临床结局，并与微生物群和免疫的协同变化相关。这些发现支持在长新冠中进一步研究以微生物群为靶点的干预措施。
Abstract
Long COVID is frequently characterized by persistent fatigue and impaired quality of life. Increasing evidence suggests that gut microbiota dysbiosis and immune dysregulation may contribute to symptom persistence. We evaluated the effects of the probiotic formulation VSL#3® in patients with long COVID. In this randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov identifier: NCT05874089), patients with long COVID and clinically relevant fatigue received VSL#3® or placebo for 4 weeks. The primary endpoint was fatigue improvement assessed by the Chalder Fatigue Scale (CFS). Secondary and exploratory analyses included patient-reported outcomes, gut microbiota profiling, immune phenotyping, cytokine analyses, and targeted metabolomics. Forty-eight patients completed the study (placebo n = 25; VSL#3® n = 23). VSL#3® supplementation significantly improved fatigue compared with placebo, with a greater reduction in CFS score (24.24% vs. 6.06%; p = 0.037) and a higher proportion of responders (68% vs. 35.7%; p = 0.019). Clinical benefit persisted after treatment discontinuation and was accompanied by improvements in selected quality-of-life and gastrointestinal symptom domains. VSL#3® supplementation was associated with selective enrichment of health-associated bacterial taxa, including , , , and , together with modulation of inflammatory and immune-related pathways. Exploratory multi-omic analyses identified coordinated associations among microbiota-derived metabolites, immune markers, and clinical outcomes. VSL#3® supplementation improved fatigue and selected clinical outcomes in patients with long COVID and was associated with coordinated microbiota and immune changes. These findings support further investigation of microbiota-targeted interventions in long COVID.
如何引用
AMA
Chiara Amoroso, Beatrice Marinoni, Paola Maragno, Alessandro Rimondi, Federico Bottaro, Clorinda Ciafardini, et al. {"_":"VSL#3 supplementation improves fatigue in long COVID: results from the DELong#3 randomized placebo-controlled trial.","sup":["®"]}. British journal of biomedical science. 2026; doi:10.3389/bjbs.2026.16993.
APA
Chiara Amoroso, Beatrice Marinoni, Paola Maragno, Alessandro Rimondi, Federico Bottaro, Clorinda Ciafardini, et al (2026). {"_":"VSL#3 supplementation improves fatigue in long COVID: results from the DELong#3 randomized placebo-controlled trial.","sup":["®"]}. British journal of biomedical science. https://doi.org/10.3389/bjbs.2026.16993
GB/T 7714
Chiara Amoroso, Beatrice Marinoni, Paola Maragno, Alessandro Rimondi, Federico Bottaro, Clorinda Ciafardini, et al. {"_":"VSL#3 supplementation improves fatigue in long COVID: results from the DELong#3 randomized placebo-controlled trial.","sup":["®"]}[J]. British journal of biomedical science, 2026 doi:10.3389/bjbs.2026.16993.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出